CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions.

CENTOGENE announced today that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His…

As part of an exchange with senior business and academic leaders, and state of Mecklenburg-Vorpommern (M-V) government representatives, a discussion…

Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)

CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the development of…

Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development

CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year

2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare…

CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development

The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded CENTOGENE…

For Further Inquiries Please Contact

Press Contact

Ben Legg

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads